Tag
The REBOOT-PARADOX trial evaluated TAVR plus medical therapy versus medical treatment alone in symptomatic paradoxical low-flow, low-gradient aortic stenosis, showing no definitive mortality benefit but supporting personalized care with tim
This analysis reveals comparable 10-year mortality, valve durability, and hemodynamics between SAPIEN 3 transcatheter and surgical aortic valve replacement in intermediate-risk patients, underscoring TAVR’s durable benefit.
The 3-year results of the LYTEN trial demonstrate that self-expanding valves provide significantly better hemodynamic performance than balloon-expandable valves for failed small surgical bioprostheses, although clinical outcomes like mortal
The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor id
